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the literature, but a few cases have been reported with
palifermin.
Objective: To determine the incidence, onset, duration,
severity and risk factors for HFS in patients receiving TBI/
VP16  palifermin, and to evaluate the effects of palifermin
on the development of HFS.
Method: An institutional review board-approved retro-
spective cohort study of adult allogeneic HSCT patients at
City of Hope receiving TBI/VP16 (control) and TBI/VP16/pal-
ifermin (palifermin) was conducted during 2 speciﬁc time
periods. The occurrence of HFS was determined through
review of medical records.
Results: Incidence of HFS was 38% and 40% in the control
(n¼58) and palifermin (n¼58) groups (Fisher's exact, P¼ .85).
Mean duration of HFS was 16.8 and 11 days (t-test, P ¼ .015).
Mean onset of HFS occurred on day +7.6 and +3.7 (t-test, P ¼
.0001). SevereHFSoccurred in43%and13% (Fisher's exact, P¼
.07). Severity of HFS was associated with duration in the
palifermin group (Spearman r¼0.85, P < .0001). Females and
patients who developed early skin reactions to palifermin
weremore likely todevelopHFS (Fisher's exact,P¼ .01 andP¼
.04). Age, donor type, and palifermin dosing schedule were
not risk factors for development of HFS.
Conclusion: TBI/VP16 was associated with a 38-40% inci-
dence of HFS. Palifermin signiﬁcantly reduced time to onset
and decreased duration of HFS and offers a previously unre-
ported beneﬁt in this patient population. Female gender and
early skin reaction to palifermin were risk factors for HFS.
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Introduction: Infection remains a major challenge in
patients undergoing stem cell transplants in developing
countries. The Tata medical Center (TMC) is a new compre-
hensive cancer center in Eastern India started in May 2011.
This abstract reviews the gut surveillance cultures for multi-
drug resistant organisms (MDROs) in our transplant patients
(SCT) in the ﬁrst 10 months of operation.
Materials and Methods: From Dec 2011 to early October
2012, information on patients undergoing SCT was reviewed.
Indications for transplant included malignant [AML, MDS,
NHL, Myeloma, Hodgkin Lymphoma] and non-malignant
conditions [Thalassemia, Aplastic Anemia, Fanconi Anemia].
Fecal Surveillance cultures were taken prior to SCT and were
carried out by a method based on Landman D et al (J Clin
Microbiol 2005). All patients received anti-fungal (pos-
aconazole in 12/21) and anti-viral prophylaxis (acyclovir 21/
21). Patients were treated in HEPA ﬁltered rooms and febrile
episodes managed as per institutional policy, initiating
therapy with amikacin and piperacillin-tazobactum.
Results and Discussion: 21 patients [16 male and 5 female]
underwent 22 hematopoietic stem cell transplant proce-
dures [15 allogeneic and 7 autologous]. Allogeneic trans-
plants included 11 matched related donor, 2 matched
unrelated donor and 2 haploidentical transplants. Medianage was 26yr [range: 6yr-60yr]. Surveillance culture was
done in 19 patients and MDROs were detected all patients.
Multiple MDRO strains were found in 11/19 patients. ESBL,
MBL and AmpC producing organisms were found in 17/19, 4/
19 and 5/19 patients respectively. Fever was documented in
all transplant patients and 15 of 213 blood cultures drawn
were positive with eight signiﬁcant isolates among which
was an MDRO Pseudomonas aeruginosa. Transplant related
mortality in three patients was attributed to sepsis in two
(pneumonia due to Aspergillus fumigatus, and Elizabethkingia
meningoseptica)and GVHD in one patient. Antimicrobial
therapy was escalated to Meropenem in 19/22, Colistin in 8/
22, Teicoplanin in 10/22, Metronidazole in 9/22, Liposomal
Amphotericin-B in 4/22, and Caspofungin in 5/22. In the 8
patients given colistin, carbapenamase positive organisms
were documented in surveillance cultures of 4.
Conclusions: The high level of antimicrobial resistance in
the enteric ﬂora of patients undergoing SCT in the devel-
opingworldwill have a signiﬁcant impact on antibiotic usage
and outcome.317
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The dose limiting toxicity of high dose melphalan condi-
tioning for autologous stem cell transplantation (HDM-ASCT)
in patients with plasma cell dyscrasias (PCD) is mucositis of
the upper and lower gastrointestinal tract. Mucositis can lead
to decreased oral intake, increased length of stay (LOS) and
gut-derived infections. Studies with transplant recipients
have shown conﬂicting results regarding the efﬁcacy of the
amino acid glutamine and the probiotic yeast Saccharomyces
boulardii (GSB) for mucositis attenuation, improvement in
gut immune barrier function, and modulation of inﬂamma-
tory cytokines. We sought to evaluate the beneﬁt of GSB on
mucosal morbidity and incidence of diarrhea at our institu-
tion, where 151 patients with PCD were transplanted
between January 2011 and July 2012.
For this retrospective casecontrol study, inclusioncriteriawere
patients with multiple myeloma and AL amyloidosis who
received HDM-ASCT either as consolidation of front-line
therapy or salvage. At our institution, based on referring
physician group preference, one group of patients with PCD
was routinely prescribed GSB while another group was not.
The 75 patients receiving supplementationwere prescribed to
take daily L-glutamine for 2 weeks, leaving a 4-day pause
before the transplant date, and daily Saccharomyces boulardii
for 2 weeks prior to the transplant, until the day of admission,
witha costofUSD83.The remaining76patientsdidnot receive
GSB. As per institutional standard of care, all subjects received
cryotherapyduringHDMinfusion for prophylaxis ofmucositis.
The charts of the 151 patients (86 males, 65 females) aged
27 - 72 years (median 61 years) who received HDM-ASCT
between January 2011 and July 2012 were reviewed. Inci-
dence of mucositis in the GSB group was 30.7% vs 34.2% in
the no GSB group. Severe mucositis, deﬁned as preventing
oral intake, occurred in 10.1% of the GSB group and 17.1% of
the no GSB group. Incidence of diarrhea in the 2 groups was
86.7% and 81.6%, in the OGP group and no GSB group,
Abstracts / Biol Blood Marrow Transplant 19 (2013) S257eS278S270respectively, with no difference in incidence of C. difﬁcile-
associated diarrhea.
Administration of GSB was well tolerated and safe, and with
no associated fungemia. The administration of GSB in the
immediate pre-transplant period did not impact LOS, inci-
dence and severity of mucositis, or incidence and volume of
diarrhea. Complete analysis and subgroup analysis are being
performed and will be presented at the meeting.
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Background: Vaccine-preventable diseases continue to pose
a risk to HSCT recipients, thus guidelines recommend routine
vaccination after HSCT. Pediatric data is limited regarding
vaccine immunogenicity post-HSCT and may contribute to
inconsistent vaccination practices.
Objective: Prospective, observational study to determine the
immunogenicity of hepatitis B, tetanus, and pneumococcal
vaccination in children after HSCT. Secondary objective was
to evaluate correlation with T&B cell numbers.
Patients and Methods: Children receiving a HSCT from
January 2010 thru October 2012were prospectively followed.
Three doses of Hepatitis, PCV 13, and Pentacel were given per
guidelines two months apart. Pre and post vaccine-speciﬁc
antibodies and T&B cell studies were performed at 6 and 12
months post-HSCT.
Results: Compliance with current vaccine recommendations
occurred in 15 of 33 (45 %) subjects. Of the 15 subjects, 12
were evaluable receiving vaccinations and lab draws
according to the predeﬁned schedule. Patient characteristics
are described in Table 1.
Time to immunization post HSCT was a median of 197
days [180-404]. 2/12 subjects were chronic GVHD patients on
immunosuppression at the time of re-vaccination. One of
these patients did not respond to vaccination. Protective
antibody levels were found for tetanus in 83% of subjects
(median of 2.6 IU/mL [range 0.1-7]) and 69% of patients for
hepatitis. 4 evaluable subjects responded to at least 1Table 1
Patient Characteristics
Male 8 (62%)
Age at transplant 7.8 (0.6-18.9)
Transplant Type
Allogeneic 11 (85%)
Autologous 2 (15%)
Donor Source
Bone marrow 7 (54%)
Peripheral blood 3 (23%)
Umbilical cord blood 3 (23%)
Preparative Regimen
Myeloablative 10 (77%)
Serotherapy 6 (60%)
Non-myeloblative 3 (23%)
Serotherapy 2 (67%)
GVHD Prophylaxis
CNI/MTX 6 (60%)
CNI/MMF 4 (40%)pneumococcal serotype, 2 of 4 (50%) to at least 6 serotypes;
3, 4, 6B, and 19F were most immunogenic. There was no
correlation between total peripheral WBC or CD3, CD8, CD19
numbers and tetanus antibody concentrations.
Conclusions: Despite the small sample size in our cohort,
hepatitis, tetanus, and pneumococcal vaccination was
immunogenic in a majority of subjects when given 6 months
post HSCT. Pneumococcal serotypes cited to cause invasive
disease post HSCT were most immunogenic, but additional
data is needed.319
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Advances in autologous and allogeneic hematopoietic stem
cell transplantation (HSCT) over the past 20 years may have
had an impact on the morbidity and mortality associated
with infections post-transplant. We sought to retrospectively
analyze the epidemiology and risk factors for bacterial,
fungal, viral, and parasitic infections 0-30 days post-trans-
plant in a cohort of 385 autologous and 759 allogeneic
pediatric HSCT recipients transplanted in a single institution
between1990 to 2009. Risk factors were evaluated using
logistic regression. Infections occurred in 98 (25%) autolo-
gous compared to 307 (40%) allogeneic HSCT patients. Gram-
positive bacterial infections were more prevalent than gram-
negative bacterial infections in both autologous (P ¼ .003)
and allogeneic (P < .0001) HSCT patients. Bacteremia
occurred in 31 (8%) autologous and 59 (8%) allogeneic HSCT
patients. Autologous HSCT patients with a diagnosis of
leukemia were at a higher risk for bacterial infections
compared to those with solid tumors (P ¼ .004, OR 2.80, 95%
CI 1.39-5.66). Infections due to fungal and parasitic patho-
gens in autologous HSCT patients were uncommon, and
occurred exclusively prior to 2000. Candidemiawas detected
in 26 (3%) and aspergillosis in 49 (6%) allogeneic recipients.
Herpes-Simplex virus was the most common cause of viral
infections in both autologous and allogeneic recipients.
Cytomegalovirus donor/recipient status increased risk for all
viral infections for allogeneic HSCT recipients (P ¼ .0004).
Only 3 (0.8%) deaths were attributed to infection after
autologous HSCT. All occurred prior to 2000 in patients
transplanted for acute myeloid leukemia. There were 8 (1%)
allogeneic HSCT patients who died of infections 0-30 days
post-transplant. This is the largest retrospective study on the
changing epidemiology of infections after autologous and
allogeneic HSCT in children and adolescents.320
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